BlinkLab (ASX:BB1) said the Rush University Medical Center in Illinois joined the US Food and Drug 510(k) registrational trial of its smartphone-based digital diagnostic test, BlinkLab Dx 1, according to a Thursday Australian bourse filing.
The pivotal study will enroll around 528 children between the ages of two and 11 years across eight leading US sites.